It is our mandate to catalyse and facilitate growth in the cell and gene therapy industry. Since our inception in 2012, we have been gathering qualitative and quantitative data to showcase the impact we are having on the companies and researchers we work with and on general industry growth.
UK companies have received
£2.5bn+investment
There are
90+
advanced therapy developers in the UK
Of UK ATMP developers
69%
have collaborated with CGT Catapult
There are
127
active clinical trials in 2019, compared to 85 in 2018
There has been a
45%
growth in UK clinical trials
There are
3,000+
jobs compared to 540 in 2012
There are
26
GMP facilities compared to 11 in 2012
There has been a
136%
increase in the number of GMP manufacturing facilities
The
7,700m2
CGT Catapult manufacturing centre opened in 2018
